The company is also changing its name to Medisys, and has appointed Michael Coy, Brian Timmons and James Chan, directors of NIC, to the board of Biocure as managing director, finance director and commercial director respectively.
Biocure is also delisting from the Official List and transferring to AIM. It will hold an EGM on 25 July to seek shareholder approval, and dealing on AIM will start on 28 July. NIC's needle disposal products are forecast to have a big impact in the US and Mexico. NIC made losses of pounds 668,000 in the year to 31 May1996, and losses of pounds 990,000 in the seven months ended 31 December 1996.Reuse content